Indeed, carriers of GBA mutations exhibit clinical features related to early-onset, levodopa-responsive PD, experiencing hallucinations and symptoms of cognitive decline or dementia, with the abundant presence of LBs in the neocortex [83]. Here, GBA1 is linked to Parkinson disease.